Trial Search Results
Breast Cancer Lymphedema: Role of Insulin Resistance/FOXC2
To better understand the mechanisms leading to lymphedema development in breast cancer survivors, and the implications for potential innovative approaches to the screening, prevention and treatment of this condition.
Stanford is currently not accepting patients for this trial.
Collaborator: California Breast Cancer Research Program
- Patients enrolled in the proposed studies must be survivors of breast cancer at a time
point at least 4 years following the initial surgery and radiotherapy for the disease.
- Patients must have a history of unilateral axillary lymph node dissection.
- Patients referred to, or that receive their care within the Stanford University Breast
Cancer Program and the Stanford Center for Lymphatic and Venous Disorders.
- Patients will be required to have the capacity to provide informed consent.
- Patients with other serious systemic illness (renal failure, hepatic dysfunction,
congestive heart failure, neurological or psychological impairment) that would
confound the study or impair the patients' ability to participate.
- Patients will not be enrolled if they are taking drugs that affect carbohydrate
- Patients with recurrent breast cancer or other forms of pre-existing lymphedema will
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study